A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The study is designed to gather the efficacy, safety and tolerability data in Japanese
children 7 to 18 years of age that would support approval of MEDI3250 in Japan.